Capricor Therapeutics

Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Capricor Therapeutics reports strong Q4 performance and advances DMD therapy

Capricor Therapeutics showcased strong financial performance, progress in DMD therapy, and strategic partnerships with Nippon Shinyaku and NS Pharma.
The company faces challenges in FDA interactions, share sales, and potential acquisition decisions, but opportunities lie in market expansion and community engagement.
Overall, Capricor's confidence in its therapies and partnerships positions it well for future growth and impact in the Duchenne Muscular Dystrophy space.
The call concluded with gratitude towards participants, supporters, and the Capricor team, highlighting a positive outlook for the company's future endeavors.

Capricor Therapeutics advances DMD programs and secures Japan distribution

Capricor Therapeutics made significant progress in Q1 2023 with advancements in DMD programs, manufacturing, and clinical trials.
While facing financial losses, the company's strategic strengths include FDA discussions, partnerships, and international expansion.
Challenges in financial stability and operational efficiency need to be addressed, but opportunities in funding, market expansion, and innovation are promising.

Capricor Therapeutics reports Q2 progress with positive clinical outcomes

Capricor Therapeutics showcased solid financial performance amid ongoing R&D investments, with a focus on advancing innovative therapies for Duchenne muscular dystrophy.
The company's strengths lie in positive clinical trial outcomes, regulatory support, and strategic board additions, positioning Capricor for future growth and success.
Challenges include financial sustainability, trial coordination, and manufacturing scalability, which require careful management to navigate effectively.
Opportunities in new indications, partnerships, upcoming milestones, and technology advancement offer avenues for expansion, value creation, and competitive differentiation.

Capricor Therapeutics achieves enrollment goal, eyes FDA approval acceleration

Capricor Therapeutics is making significant strides in its clinical trials and manufacturing capabilities, supported by a strong financial position. While challenges exist in managing expenses and navigating regulatory processes, the company is well-positioned to capitalize on growth opportunities in the biopharmaceutical sector.

Capricor Therapeutics reports positive trial results and strategic partnerships for growth

Capricor Therapeutics' Q4 2023 performance reflects a strong financial position but with a net loss, driven by positive trial results for CAP-1002 in DMD.
The company's strengths include successful trial outcomes, strategic partnerships, and advancements in exosome technology development.
Challenges include operational losses, regulatory hurdles, and market competition, while opportunities exist in partnerships, FDA interactions, and technology development.
Overall, Capricor Therapeutics is poised for growth with a focus on commercialization, regulatory progress, and expanding therapeutic applications.

Capricor Therapeutics excels in Q1 2024, poised for market expansion

Capricor Therapeutics shows strong financial performance and progress in DMD trial, positioning CAP-1002 favorably in the market.
Strategic focus on regulatory alignment, commercial readiness, and potential expansions highlight growth opportunities.
Challenges in regulatory compliance, operational execution, and market competition require proactive management strategies.
Overall, Capricor's advancements in therapy development and market positioning indicate a promising outlook for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

-Statistically Significant Results in Performance of the Upper Limb PUL 2.0 (p=0.02) Extended to 18 Months, Demonstrating Long-Term Benefit in Skeletal Muscle Function-

Capricor Therapeutics Announces Positive 18-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Patients

-Company to present 18-month data results from ongoing HOPE-2 open label extension trial of CAP-1002 in patients with Duchenne muscular dystrophy-

Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Provide Recent Updates on CAP-1002 Program

-StealthX™   Exosome Platform Shows Multivalent Vaccine Induces Long-Lasting Immunity to Multiple SARS-CoV-2 Proteins-

Capricor Announces Publication Highlighting New Advances for its Engineered Exosome Platform

Capricor (CAPR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Capricor (CAPR) Upgraded to Buy: What Does It Mean for the Stock?

Capricor Therapeutics, Inc. (NASDAQ:CAPR ) Q3 2022 Results Conference Call November 10, 2022 4:30 PM ET Company Participants AJ Bergmann - CFO Linda Marbán - CEO Conference Call Participants Alan Leong - BioWatch News Aydin Huseynov - Ladenburg Brian Corday - BullBear Partners Operator Good day, ladies and gentlemen, and welcome to the Capricor Therapeutics Incorporated Third Quarter 2022 Earnings Call. Today's conference is being recorded.

Capricor Therapeutics, Inc. (CAPR) Q3 2022 Earnings Call Transcript

Capricor (CAPR) delivered earnings and revenue surprises of 7.14% and 279.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Capricor Therapeutics (CAPR) Reports Q3 Loss, Tops Revenue Estimates

-Enrollment Continues to Progress in HOPE-3, the Pivotal Phase 3 Clinical Trial of CAP-1002 in Duchenne Muscular Dystrophy-

Capricor Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Company to Host Conference Call, November 10, 2022, at 4:30 p.m. ET Company to Host Conference Call, November 10, 2022, at 4:30 p.m. ET

Capricor Therapeutics to Present Third Quarter 2022 Financial Results and Recent Corporate Update on November 10

SAN DIEGO, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today that the Company will present one-year safety and efficacy results from its HOPE-2 open-label extension study with lead asset CAP-1002 for treating Duchenne muscular dystrophy (DMD). These data will be featured in a poster presentation at this year's World Muscle Society Congress (WMS) being held both virtually and in Halifax, Nova Scotia, Canada from October 11-15, 2022.

Capricor Therapeutics to Present One-Year Results from HOPE-2 Open Label Extension Study at World Muscle Society 2022

Capricor Therapeutics, Inc. (NASDAQ:CAPR ) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Anthony Bergmann - CFO Linda Marbán - President and CEO Conference Call Participants Joe Pantginis - H.C. Wainwright Operator Good day and welcome to the Capricor Therapeutics' Second Quarter 2022 Earnings Call.

Capricor Therapeutics, Inc. (CAPR) CEO Linda Marbán on Q2 2022 Results Earnings Call Transcript

-First Patient Treated in HOPE-3, the Pivotal Phase 3 Clinical Trial of CAP-1002 in Duchenne Muscular Dystrophy-

Capricor Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Company to Host Conference Call, August 10, 2022, at 4:30 p.m. ET Company to Host Conference Call, August 10, 2022, at 4:30 p.m. ET

Capricor Therapeutics to Present Second Quarter 2022 Financial Results and Recent Corporate Update on August 10

-Double-Blind, Randomized, Placebo-Controlled HOPE-3 Clinical Trial Designed to Enroll approximately 70 Patients-

Capricor Therapeutics Announces First Patient Dosed in Pivotal Phase 3 Study of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy

-Met Primary Endpoint of Performance of the Upper Limb PUL 2.0 (p=0.02)-

Capricor Therapeutics Announces Statistically Significant Clinical Benefits in Skeletal Muscle Function in Non-Ambulant Duchenne Muscular Dystrophy Patients Treated with CAP-1002 in HOPE-2 Open Label Extension Study

Results to be Presented in Late-Breaking Session Results to be Presented in Late-Breaking Session

Capricor Therapeutics to Present One-Year Efficacy Results from its Ongoing HOPE-2 Open Label Extension Study at 2022 Parent Project Muscular Dystrophy Annual Conference

Capricor Expands Senior Management Team to Build Commercial Strategy for Lead Asset, CAP-1002, and Further Develop Partnering Strategy for Proprietary Exosome Platform

Capricor Therapeutics Appoints Xavier Avat as Chief Business Officer

SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today that Dr. Linda Marbán, CEO of Capricor, will present at the H.C. Wainwright Global Investment Conference being held on May 23-26, 2022 in Miami, Florida. Please see additional presentation details below:

Capricor Therapeutics to Present at the H.C. Wainwright Global Investment Conference

Capricor Therapeutics, Inc. (NASDAQ:CAPR ) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Anthony Bergmann - CFO & Corporate Treasurer Linda Marban - Co-Founder, President, CEO & Director Conference Call Participants Joseph Pantginis - H.C. Wainwright & Co. Operator Good day, ladies and gentlemen, and welcome to the Capricor Therapeutics, Inc. First Quarter 2022 Financial Earnings Call.

Capricor Therapeutics, Inc. (CAPR) CEO Linda Marban on Q1 2022 Results - Earnings Call Transcript

-Executed Partnership with Nippon Shinyaku for the Commercialization and Distribution of  CAP-1002 for Duchenne Muscular Dystrophy in the United States-

Capricor Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

Company to Host Conference Call, May 10, 2022, at 4:30 p.m. ET Company to Host Conference Call, May 10, 2022, at 4:30 p.m. ET

Capricor Therapeutics to Present First Quarter 2022 Financial Results and Recent Corporate Update on May 10

Charah Solutions Inc

FGI Industries Ltd

Lipocine

Profire Energy

Seanergy Maritime Hlds

Vista Gold

Each of these penny stocks has proven momentum throughout 2022 and major upside on top of the returns through the the first quarter. The post 7 Undervalued Penny Stocks With Major Upside appeared first on InvestorPlace.

7 Undervalued Penny Stocks With Major Upside

SAN DIEGO, March 29, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today that Dr. Linda Marbán, CEO of Capricor, will participate in a panel discussion at the virtual Cantor Fitzgerald Rare Orphan Disease Summit on March 30, 2022. Please see additional panel details below:

Capricor Therapeutics to Participate in the Cantor Fitzgerald Rare Orphan Disease Summit

Capricor Therapeutics Inc (NASDAQ: CAPR) announced topline data from its Phase 2 INSPIRE study evaluating a single-dose intravenous infusion of CAP-1002 for hospitalized COVID-19 patients. Capricor said that the trial met its primary objective of safety.

Capricor Shares Fall After Topline Results From Mid-Stage COVID-19 Trial

-Primary Objective of Study Met: CAP-1002 was Safe and Well Tolerated-

Capricor Therapeutics Reports Topline Results from Phase 2 Exploratory INSPIRE Trial in Severe Hospitalized COVID-19 Patients

-One-Year Final Data Highlights Lead Cell Therapy Asset, CAP-1002, for Safety and Efficacy in Slowing Upper Limb and Cardiac Function Deterioration in Patients-

News for Capricor Therapeutics Stock (CAPR)